Even in the non-cirrhotic group, the annual incidence of HCC increased from 0.07% in F0 and F1 to 2.2% in F3 patients with non-sustained virologic response to initial IFN therapy (5). Here, IFNA1 is linked to hepatocellular carcinoma.